ÂÜÀòÂÒÂ×

Mr. Schor has served as Adicet’s President, Chief Executive Officer and Director since its merger with resTORbio in September 2020. He held the role of President and Chief Executive Officer at resTORbio since co-founding the company in 2016. Mr. Schor has led biotech companies across all stages, from formation and early-stage discovery to a publicly traded multi-product company with significant big pharma partnerships. Prior to co-founding resTORbio, Mr. Schor led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL). Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals, and in leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor holds an M.B.A., a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).s